SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Alpha Capital Anstalt – ‘SC 13G’ on 2/5/20 re: Accelerated Pharma, Inc.

On:  Wednesday, 2/5/20, at 11:28am ET   ·   Accession #:  1213900-20-2643   ·   File #:  5-91324

Previous ‘SC 13G’:  ‘SC 13G/A’ on 1/16/20   ·   Next:  ‘SC 13G’ on 3/25/20   ·   Latest:  ‘SC 13G’ on 3/18/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/05/20  Alpha Capital Anstalt             SC 13G                 1:38K  Accelerated Pharma, Inc.          Edgar Agents LLC/FA

Statement of Acquisition of Beneficial Ownership by a Passive Investor   —   Sch. 13G
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G      Statement of Acquisition of Beneficial Ownership    HTML     21K 
                by a Passive Investor                                            


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. ___)

 

ACCELERATED PHARMA, INC.

 

(Name of Issuer)

 

COMMON STOCK, PAR VALUE $0.001

 

(Title of Class of Securities)

 

 

 

(CUSIP Number)

 

December 31, 2019

 

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the

disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following page(s)

 

Page 1 of 5 Pages

 

 

 

 C: 

 

 

 

CUSIP No. 13G Page 2 of 5 Pages

 

1. NAMES OF REPORTING PERSON
  S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
  Alpha Capital Anstalt
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
    (a) ☐
    (b) ☐
3. SEC USE ONLY
   
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  Liechtenstein

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
5. SOLE VOTING POWER,– 225,638 Shares (1)
   
6. SHARED VOTING POWER - None
   
7. SOLE DISPOSITIVE POWER – 225,638 Shares (1)
   
8. SHARED DISPOSITIVE POWER – None
   

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -  
  225,638 Shares (1)  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ 
     
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
  5.33%  
12. TYPE OF REPORTING PERSON  
  CO  

 

(1) Based on 4,231,421 shares outstanding following a 1.47 for 1 reverse split of 6,220,190 shares outstanding as of June 30, 2019 as described in the Issuer’s registration statement declared effective on November 7, 2019.

 

 C: 

 

 

 

CUSIP No. 13G Page 3 of 5 Pages

 

ITEM 1(a) NAME OF ISSUER: Accelerated Pharma, Inc.

 

ITEM 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

 

15W155 81st Street, Burr Ridge, IL 60527

 

ITEM 2(a) NAME OF PERSON FILING: Alpha Capital Anstalt

 

ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

 

ITEM 2(c) CITIZENSHIP: Liechtenstein

 

ITEM 2(d) TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001

 

ITEM 2(e) CUSIP NUMBER:

 

ITEM 3IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

 

ITEM 4OWNERSHIP

 

(a) AMOUNT BENEFICIALLY OWNED: 225,638 Shares (1)

 

(b) PERCENT OF CLASS: 5.33%

 

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

 

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

 

225,638 Shares (1)

 

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

 

0 Shares

 

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

225,638 Shares (1)

 

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

0 Shares

 

 C: 

 

 

 

CUSIP No. 13G Page 4 of 5 Pages

 

ITEM 5OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

Not applicable

 

ITEM 6OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

Not applicable

 

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

Not applicable

 

ITEM 8IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

 

Not applicable

 

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

 

Not applicable

 

 C: 

 

 

 

CUSIP No. 13G Page 5 of 5 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  February 4, 2020
  (Date)
   
  /s/ Konrad Ackermann
  (Signature)
   
  Konrad Ackermann, Director
  (Name/Title)

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘SC 13G’ Filing    Date    Other Filings
Filed on:2/5/20
2/4/20
12/31/19
11/7/19EFFECT
6/30/19
 List all Filings 
Top
Filing Submission 0001213900-20-002643   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 11:28:58.1pm ET